Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Intravitreal Bevacizumab for the Treatment of Patients With Low Vision Due to Neovascular Age-related Macular Degeneration
Authors not listed
IRCCS San Raffaele · 2011
Abstract
The purpose of this study is to compare the effectiveness of intravitreal bevacizumab injection (IVBI) with respect to simple observation in patients with subfoveal choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD) presenting at baseline with best corrected visual acuity (BCVA) less than 20/200.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-12 MST
Cite this
APA
Anonymous. (2011). Intravitreal Bevacizumab for the Treatment of Patients With Low Vision Due to Neovascular Age-related Macular Degeneration. <em>IRCCS San Raffaele</em>. https://clinicaltrials.gov/study/NCT01327222
Vancouver
Anonymous. Intravitreal Bevacizumab for the Treatment of Patients With Low Vision Due to Neovascular Age-related Macular Degeneration. IRCCS San Raffaele. 2011.
BibTeX
@misc{anon2011Intrav,
title = {Intravitreal Bevacizumab for the Treatment of Patients With Low Vision Due to Neovascular Age-related Macular Degeneration},
author = {Anonymous},
journal = {IRCCS San Raffaele},
year = {2011},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Clinical Interventions in Aging 2006
Open access · OA
Ranibizumab in neovascular age-related macular degeneration
Ophthalmology 2012
Preprint · OA
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
University of California, Los Angeles 2009
Open access · US-GOV
Resolution of Vitreomacular Adhesion (VMA) Associated With Neovascular Age Related Macular Degeneration (AMD) With Intravitreal Microplasmin
Ophthalmology 2006
Citation only
Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration
Novartis Pharmaceuticals 2013
Open access · US-GOV
A 12-month, Phase 3b, Randomized, Visual Acuity Assessor-masked, Multicenter Study Assessing the Efficacy and Safety of Ranibizumab 0.5mg in Treat and Extend Regimen Compared to Monthly Regimen, in Patients With Neovascular Age-related Macular Degeneration
Grifols Therapeutics LLC 2004
Open access · US-GOV